Circassia Pharmaceutical PLC | Ownership
Companies that own Circassia Pharmaceutical PLC
Invesco Asset Management Ltd.
86,294,400
24.16%
-221,673
0.11%
07/18/2018
Woodford Investment Management Ltd.
78,965,981
22.11%
5,548,174
0.53%
07/18/2018
OppenheimerFunds, Inc.
32,540,657
9.11%
2,142,981
0.02%
04/12/2017
Neptune Investment Management Ltd.
16,649,900
4.66%
0
0.52%
06/14/2017
Aviva Investors Global Services Ltd.
9,755,411
2.73%
-3,321,746
0.02%
06/08/2018
Legal & General Investment Management Ltd.
3,415,000
0.96%
41,000
0%
08/01/2018
Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)
2,241,000
0.63%
73,000
0%
08/01/2018
Deutsche Investment Management Americas, Inc.
2,218,000
0.62%
0
0.01%
08/01/2018
Hargreaves Lansdown Stockbrokers Ltd.
1,992,000
0.56%
159,000
0.01%
08/01/2018
Aberdeen Asset Investments Ltd.
1,213,484
0.34%
19,677
0%
11/30/2017
| Address |
Northbrook House
Oxford Oxfordshire OX4 4GA
United Kingdom
|
|
Employees
|
- |
| Website |
http://circassia.com |
| Updated |
07/08/2019 |
| Circassia Pharmaceuticals Plc is a biopharmaceutical company, which engages in the development and commercialization of allergy, asthma, and respiratory products. It operates through the following segments: NIOX, Respiratory, and US AZ Collaboration. The NIOX segment provides a portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide. |
